Head & Neck/Thyroid Cancers
News
Disruptions in cancer care in the era of COVID-19
Conference Coverage
RT plus checkpoint blockade active in head and neck cancer
At 2 years, the progression-free survival rate was 71%, and the overall survival rate was 75%.
News
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
Latest News
Multimodal therapies almost double survival in anaplastic thyroid cancer
CHICAGO – One cancer center’s experience shows that a targeted, multidisciplinary approach makes a difference.
Conference Coverage
Toward Improving the Delivery of Oral Anticancer Drugs in the VA: Work IN PROGRESS
Conference Coverage
Evaluation of the Implementation of a 90-Minute Rituximab Infusion Protocol at the Richard L. Roudebush VA Medical Center
Conference Coverage
Improving Oral Chemotherapy Documentation Using QOPI Audit, Plan-Do-Study-Act Cycles, and the Electronic Medical Record
Conference Coverage
Radiation Therapy Treatment Breaks and Weight Changes in Head and Neck Cancer Patients in a Veterans Affairs Radiation Oncology Clinic
Conference Coverage
Benefits of Psychosocial Participation in a Head and Neck Cancer Tumor Board at the VA Palo Alto Health Care System: Two Case Examples
News
Immune-related toxicities, hospitalization common with checkpoint inhibitor therapy
The most common immune-related adverse events warranting hospital admission were pneumonitis and colitis.
